[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Pipeline Review, H2 2018

August 2018 | 84 pages | ID: ACE7C3AB34AEN
Global Markets Direct

US$ 3,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Pipeline Review, H2 2018

SUMMARY

According to the recently published report 'Aurora Kinase A - Pipeline Review, H2 2018'; Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) pipeline Target constitutes close to 17 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Aurora kinase A also known as serine/threonine-protein kinase 6 is an enzyme that contributes to the regulation of cell cycle progression. It plays a critical role in various mitotic events including the establishment of mitotic spindle, centrosome duplication, centrosome separation as well as maturation, chromosomal alignment, spindle assembly checkpoint, and cytokinesis. It is required for initial activation of CDK1 at centrosomes and normal axon formation. It phosphorylates numerous target proteins, including ARHGEF2, BORA, BRCA1, CDC25B, DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1, TACC3, p53/TP53 and TPX2. It regulates KIF2A tubulin depolymerase activity.

The report 'Aurora Kinase A - Pipeline Review, H2 2018' outlays comprehensive information on the Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 5, 2 and 7 respectively.

Similarly, the universities portfolio in IND/CTA Filed and Preclinical stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Solid Tumor, Anaplastic Large Cell Lymphoma (ALCL), Breast Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Gastric Cancer, Hepatocellular Carcinoma, Neuroblastoma, Anaplastic Astrocytoma, B-Cell Chronic Lymphocytic Leukemia, Bladder Cancer, Brain Tumor, Burkitt Lymphoma, Central Nervous System (CNS) Tumor, Colorectal Cancer, Cutaneous Angiosarcoma, Diffuse Large B-Cell Lymphoma, Ependymoma, Follicular Lymphoma, Glioblastoma Multiforme (GBM), Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, High-Grade Glioma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Kidney Cancer (Renal Cell Cancer), Lymphoma, Malignant Pleural Mesothelioma, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Nasopharyngeal Cancer, Neuroendocrine Cancer, Oligodendroglioma, Ovarian Cancer, Pancreatic Cancer, Peripheral T-Cell Lymphomas (PTCL), Pilocytic Astrocytoma, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Subependymal Giant Cell Astrocytoma, Testicular Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape for Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1)
  • The report reviews Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Overview
Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Companies Involved in Therapeutics Development
AbbVie Inc
AlfaSigma SpA
Amgen Inc
CASI Pharmaceuticals Inc
Cielo Therapeutics Inc
Merck & Co Inc
Millennium Pharmaceuticals Inc
Sanofi
Sareum Holdings Plc
Taiho Pharmaceutical Co Ltd
Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Drug Profiles
AK-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alisertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-900 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCT-137690 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
danusertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DBPR-114 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENMD-2076 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ilorasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-156497 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Aurora A Kinase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit AURKA and AURKB for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-5589 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAS-119 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TT-00420 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TY-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Dormant Products
Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Discontinued Products
Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Jun 25, 2018: Combination Therapy May Revive Prospects for Embattled Breast Cancer Drugs
Dec 21, 2017: Sundia Congratulates NHRI for DBPR114 IND Approval in US & Taiwan
Dec 01, 2017: CASI Pharmaceuticals Announces Poster Presentation At The 2017 San Antonio Breast Cancer Symposium (SABCS) On ENMD-2076 In Patients With Triple-Negative Breast Cancer (TNBC)
Sep 07, 2017: CASI Provides Update on its Cancer Drug Candidate, ENMD-2076
May 30, 2017: CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Clear Cell Ovarian Carcinoma
May 18, 2017: CASI Pharmaceuticals Announces Abstract On ENMD-2076 In Clear Cell Ovarian Cancer
Apr 14, 2017: CASI Pharmaceuticals Reports On Enrollment Status Of ENMD-2076 Phase 2 Study In Triple-Negative Breast Cancer
Mar 28, 2017: CASI Pharmaceuticals Announces Poster Presentations At AACR Annual Meeting
Aug 16, 2016: CASI Pharmaceuticals Provides Update On Phase 2 Trial Of ENMD-2076 In Fibrolamellar Carcinoma
Aug 03, 2016: China and Hong Kong Patent Grants for Sareum’s Aurora+FLT3 Kinase Inhibitors
Jun 01, 2016: CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Ovarian Clear Cell Carcinoma
May 12, 2016: CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For Fibrolamellar Carcinoma (FLC)
Nov 08, 2015: Data On Anti-Tumor Activity Of ENMD-2076 In Triple Negative Breast Cancer Animal Models Presented In Poster Session At AACR-NCI-EORTC International Conference
Nov 05, 2015: Poster For ENMD-2076 Phase 2 Trial In Soft Tissue Sarcoma Presented At The 2015 Connective Tissue Oncology Society Annual Meeting
Nov 04, 2015: CASI Pharmaceuticals Announces First Patient Dosed In Phase 2 Trial For ENMD-2076 In Fibrolamellar Carcinoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.2), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AbbVie Inc, H2 2018
Pipeline by AlfaSigma SpA, H2 2018
Pipeline by Amgen Inc, H2 2018
Pipeline by CASI Pharmaceuticals Inc, H2 2018
Pipeline by Cielo Therapeutics Inc, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by Millennium Pharmaceuticals Inc, H2 2018
Pipeline by Sanofi, H2 2018
Pipeline by Sareum Holdings Plc, H2 2018
Pipeline by Taiho Pharmaceutical Co Ltd, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Dormant Products, H2 2018 (Contd.3), H2 2018
Dormant Products, H2 2018 (Contd.4), H2 2018
Dormant Products, H2 2018 (Contd.5), H2 2018
Dormant Products, H2 2018 (Contd.6), H2 2018
Discontinued Products, H2 2018
Discontinued Products, H2 2018 (Contd.1), H2 2018

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018

COMPANIES MENTIONED

AbbVie Inc
AlfaSigma SpA
Amgen Inc
CASI Pharmaceuticals Inc
Cielo Therapeutics Inc
Merck & Co Inc
Millennium Pharmaceuticals Inc
Sanofi
Sareum Holdings Plc
Taiho Pharmaceutical Co Ltd


More Publications